MetaCap

Disc Medicine (IRON) vs Tango Therapeutics (TNGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tango Therapeutics (TNGX) has outperformed Disc Medicine (IRON) over the past year, gaining 116.7% versus a loss of 18.9%. Over five years, TNGX leads with a +110.0% price change compared with -14.2% for IRON. Tango Therapeutics is the larger company by market cap ($3.68 billion vs $3.42 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRON-18.86%TNGX+116.65%
+241%+94%-53%
Nov 21, 20251 yearNov 20, 2026
IRON-22.46%TNGX+81.54%
+176%+36%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRON versus TNGX key metrics
MetricIRONTNGX
Share price$75.14$21.73
Market cap$3.42B$3.68B
1-day change-1.27%-4.32%
YTD return-5.38%+145.26%
1-year return-18.86%+116.65%
5-year return-14.22%+109.95%
EPS (TTM)$-6.34$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$62.38M
Revenue growth (YoY)—+48.29%
Net income (latest FY)$-212.18M$-101.59M
Operating margin—-178.39%
Net margin—-162.85%
52-week high$99.50$34.39
52-week low$40.00$8.30
Distance from 52-week high-24.48%-36.81%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+69.94%+116.29%
Average volume951.56K3.41M
Shares outstanding45.54M169.46M
Employees173137
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TNGX has outperformed IRON by 135.5 percentage points over the past year.

About Disc Medicine

IRON stock →

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 173 employees

About Tango Therapeutics

TNGX stock →

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees

IRON vs TNGX FAQ

Which is bigger, Disc Medicine or Tango Therapeutics?

Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.68B compared with $3.42B for Disc Medicine (IRON).

Which stock has performed better over the past year, IRON or TNGX?

TNGX returned +116.65% over the past 12 months, compared with -18.86% for IRON (price return, excluding dividends). Past performance does not predict future results.

Are Disc Medicine and Tango Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons